Healthcare / BiotechnologyTaipei Exchange
$66.80
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-176.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.9B
P/E
22.0x
↑EV/EBITDA
14.5x
↑ROE
9.7%
↑Gross Margin
30.4%
↓Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+56.9%
FCF CAGR
—
FCF margin
-44.0%
FCF / Net income
-3.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $538.6M · net income $75.3M · FCF $-236.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $538.6M | $538.6M | $435.1M | $403.6M | $139.4M |
| Net Income | $75.3M | $75.3M | $66.8M | $82.4M | $29.6M |
| EBITDA | $136.0M | $136.0M | $114.3M | $129.5M | $57.6M |
| EPS | — | — | 3.01 | 4.24 | 2.27 |
| Gross Margin | 30.4% | 30.4% | 31.8% | 37.4% | 35.8% |
| Operating Margin | 17.1% | 17.1% | 19.4% | 25.5% | 23.7% |
| Net Margin | 14.0% | 14.0% | 15.3% | 20.4% | 21.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.30 | 0.30 | 0.44 | 0.89 | 0.55 |
| Cash Flow | |||||
| Free Cash Flow | $-236.8M | $-236.8M | $-50.2M | $-176.2M | $79.9M |
| Returns | |||||
| ROE | 9.7% | 9.7% | 14.1% | 32.1% | 21.2% |
| Valuation | |||||
| P/E | 21.97 | 21.97 | 24.58 | — | — |
| EV/EBITDA | 14.52 | 14.52 | 15.16 | — | — |
| P/B | 2.40 | 2.40 | 3.48 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 23.8% | 23.8% | 7.8% | 189.4% | — |
| EPS Growth | — | — | -29.0% | 86.5% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.7%
Start / end P/E
n/dx → n/dx
EPS bridge
3.01 → n/d
Residual
-3.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.